Calamos Wealth Management LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 6.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 4,798 shares of the healthcare product maker’s stock after purchasing an additional 281 shares during the quarter. Calamos Wealth Management LLC’s holdings in Abbott Laboratories were worth $417,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of ABT. 1 North Wealth Services LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth $38,000. Marquette Asset Management LLC increased its position in shares of Abbott Laboratories by 173.4% during the third quarter. Marquette Asset Management LLC now owns 473 shares of the healthcare product maker’s stock worth $40,000 after buying an additional 300 shares during the period. Canton Hathaway LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth $42,000. Corbenic Partners LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $42,000. Finally, Atwater Malick LLC acquired a new stake in Abbott Laboratories in the third quarter worth $65,000. Institutional investors own 73.59% of the company’s stock.
A number of research firms have commented on ABT. Guggenheim cut shares of Abbott Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, January 2nd. Credit Suisse Group raised their price target on shares of Abbott Laboratories from $95.00 to $98.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Morgan Stanley raised their price target on shares of Abbott Laboratories from $93.00 to $101.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. William Blair restated an “underperform” rating on shares of Abbott Laboratories in a report on Thursday, October 17th. Finally, ValuEngine cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $91.42.
In other news, SVP Randel William Woodgrift sold 21,000 shares of Abbott Laboratories stock in a transaction dated Wednesday, October 23rd. The shares were sold at an average price of $80.54, for a total transaction of $1,691,340.00. Following the completion of the transaction, the senior vice president now directly owns 68,562 shares in the company, valued at $5,521,983.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.70% of the stock is owned by company insiders.
NYSE:ABT opened at $87.38 on Thursday. The company has a current ratio of 1.54, a quick ratio of 1.12 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $151.63 billion, a price-to-earnings ratio of 30.34, a PEG ratio of 2.20 and a beta of 1.12. The firm has a fifty day simple moving average of $86.11 and a two-hundred day simple moving average of $84.56. Abbott Laboratories has a 12 month low of $68.80 and a 12 month high of $89.24.
Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $0.84 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.84. The firm had revenue of $8.08 billion during the quarter, compared to analysts’ expectations of $8.10 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 17.65%. The business’s revenue was up 5.5% on a year-over-year basis. During the same period last year, the company earned $0.75 earnings per share. Equities analysts predict that Abbott Laboratories will post 3.24 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be issued a dividend of $0.36 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.32. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.65%. The ex-dividend date of this dividend is Tuesday, January 14th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 50.00%.
About Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Further Reading: Which market index is the best?
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.